New drug cocktail aims to fight Tough-to-Treat breast cancer
NCT ID NCT02393794
Summary
This study is testing whether combining three drugs—cisplatin, romidepsin, and nivolumab—is safe and effective for controlling advanced breast cancer that has spread or returned. It focuses on two specific groups: patients with triple-negative breast cancer or those with a BRCA gene mutation. The goal is to find a new treatment option for people who have few choices left after standard chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Kansas Cancer Center - Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154, United States
-
University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, 66210, United States
-
University of Kansas Cancer Center - South
Kansas City, Missouri, 64131, United States
-
University of Kansas Cancer Center - West
Kansas City, Kansas, 66112, United States
-
University of Kansas Cancer Center - Westwood
Westwood, Kansas, 66205, United States
Conditions
Explore the condition pages connected to this study.